Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs
Dong Han, … , Xiaohong Li, Changmeng Cai
Dong Han, … , Xiaohong Li, Changmeng Cai
Published April 30, 2024
Citation Information: J Clin Invest. 2024;134(11):e168649. https://doi.org/10.1172/JCI168649.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 9

Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs

  • Text
  • PDF
Abstract

One critical mechanism through which prostate cancer (PCa) adapts to treatments targeting androgen receptor (AR) signaling is the emergence of ligand-binding domain–truncated and constitutively active AR splice variants, particularly AR-V7. While AR-V7 has been intensively studied, its ability to activate distinct biological functions compared with the full-length AR (AR-FL), and its role in regulating the metastatic progression of castration-resistant PCa (CRPC), remain unclear. Our study found that, under castrated conditions, AR-V7 strongly induced osteoblastic bone lesions, a response not observed with AR-FL overexpression. Through combined ChIP-seq, ATAC-seq, and RNA-seq analyses, we demonstrated that AR-V7 uniquely accesses the androgen-responsive elements in compact chromatin regions, activating a distinct transcription program. This program was highly enriched for genes involved in epithelial-mesenchymal transition and metastasis. Notably, we discovered that SOX9, a critical metastasis driver gene, was a direct target and downstream effector of AR-V7. Its protein expression was dramatically upregulated in AR-V7–induced bone lesions. Moreover, we found that Ser81 phosphorylation enhanced AR-V7’s pro-metastasis function by selectively altering its specific transcription program. Blocking this phosphorylation with CDK9 inhibitors impaired the AR-V7–mediated metastasis program. Overall, our study has provided molecular insights into the role of AR splice variants in driving the metastatic progression of CRPC.

Authors

Dong Han, Maryam Labaf, Yawei Zhao, Jude Owiredu, Songqi Zhang, Krishna Patel, Kavita Venkataramani, Jocelyn S. Steinfeld, Wanting Han, Muqing Li, Mingyu Liu, Zifeng Wang, Anna Besschetnova, Susan Patalano, Michaela J. Mulhearn, Jill A. Macoska, Xin Yuan, Steven P. Balk, Peter S. Nelson, Stephen R. Plymate, Shuai Gao, Kellee R. Siegfried, Ruihua Liu, Mary M. Stangis, Gabrielle Foxa, Piotr J. Czernik, Bart O. Williams, Kourosh Zarringhalam, Xiaohong Li, Changmeng Cai

×

Figure 7

Ser81 phosphorylation is required for AR-V7–induced metastasis.

Options: View larger image (or click on image) Download as PowerPoint
Ser81 phosphorylation is required for AR-V7–induced metastasis.
(A) Immu...
(A) Immunoblotting for indicated proteins in C4-2-tet-ARV7 and C4-2-ARV7S81A cells (C4-2 cells expressing doxycycline-regulated V5-tagged AR-V7-S81A mutant) treated with 0–1 μg/mL doxycycline for 48 hours. (B) C4-2-ARV7S81A cells were injected into the tibias of castrated male mice, which were then fed with or without a doxycycline-supplemented diet. The bone lesion area was monitored and quantified. Note: this experiment was conducted simultaneously with the C4-2-tet-ARV7 and C4-2-tet-ARFL experiments shown in Figure 1. (C) Normalized bone volume and trabecular bone number were compared. (D) Structure views of bones scanned by μCT and 3D reconstructed. (E) IHC staining for SOX9 in tumor samples. Scale bars: 500 μm (left) and 100 μm (right). (F) Zebrafish embryo metastasis assay in GFP-labeled C4-2-tet-ARV7WT and C4-2-tet-ARV7S81A cells pretreated with or without 0.25 μg/mL doxycycline for 48 hours. All the cell lines were hormone depleted before experiments. **P < 0.01; ***P < 0.001 by unpaired, 2-sided Student’s t test (B, C, and E) or Fisher’s exact test (F).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Posted by 5 X users
21 readers on Mendeley
See more details